Response gene to complement‑32 promotes cell survival via the NF‑κB pathway in non‑small‑cell lung cancer

Zhang,Jing; Lei,Jun‑Rong; Yuan,Ling‑Ling; Wen,Ru; Yang,Jiong

doi:10.3892/etm.2019.8177

Response gene to complement‑32 promotes cell survival via the NF‑κB pathway in non‑small‑cell lung cancer

Authors:
- Jing Zhang
- Jun‑Rong Lei
- Ling‑Ling Yuan
- Ru Wen
- Jiong Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
Published online on: November 8, 2019 https://doi.org/10.3892/etm.2019.8177
Pages: 107-114
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Response gene to complement (RGC)‑32 regulates the cell cycle in response to complement activation. The present study demonstrated that the expression level of RGC‑32 is higher in human non‑small‑cell lung cancer (NSCLC) tissues compared with health controls. Overexpressing RGC‑32 induced p65 nucleus translocation, significantly increased nuclear p65 levels and promoted the proliferation of A549 cells. Knockdown of RGC‑32 by short hairpin RNA decreased the expression level of nuclear p65 and inhibited cell proliferation. The increase in cell proliferation induced by RGC32 could be abolished by the NF‑κB inhibitor pyrrolidine dithiocarbamate. Mechanistic studies indicated that RGC32 mediated NF‑κB downstream genes, including vascular cell adhesion protein 1, interleukin‑6, cyclin dependent kinase inhibitor 2C, testin and vascular endothelial growth factor A. In summary, the present study demonstrated a novel role of RGC‑32 in the progression of NSCLC via the NF‑κB pathway and p65. Therefore, RGC‑32 could be a potential therapeutic target for NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Liu WJ, Zhu KL, Xu J, Wang JL and Zhu H: Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma. Lab Invest. 98:1538–1545. 2018. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
4	Xu J, Du Y, Liu XJ, Zhu BY, Zhang SH, Li L, Li Y, Wang XF, Shan CK, Wang RQ and Zhen YS: Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacol Res. 126:66–76. 2017. View Article : Google Scholar : PubMed/NCBI
5	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
6	Sun YW, Xu J, Zhou J and Liu WJ: Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 9:5459–5472. 2018. View Article : Google Scholar : PubMed/NCBI
7	Wen R, Umeano AC, Chen P and Farooqi AA: Polymer-based drug delivery systems for cancer. Crit Rev Ther Drug Carrier Syst. 35:521–553. 2018. View Article : Google Scholar : PubMed/NCBI
8	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
9	Basu U, Banik B, Wen R, Pathak RK and Dhar S: The platin-X series: Activation, targeting, and delivery. Dalton Trans. 45:12992–13004. 2016. View Article : Google Scholar : PubMed/NCBI
10	Pathak RK, Wen R, Kolishetti N and Dhar S: A prodrug of two approved drugs, cisplatin and chlorambucil, for chemo war against cancer. Mol Cancer Ther. 16:625–636. 2017. View Article : Google Scholar : PubMed/NCBI
11	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wysoczynski M and Ratajczak MZ: Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors. Int J Cancer. 125:1595–1603. 2009. View Article : Google Scholar : PubMed/NCBI
13	Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda FJ and Montuenga LM: Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia. 9:840–852. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lee JI and Burckart GJ: Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol. 38:981–993. 1998. View Article : Google Scholar : PubMed/NCBI
15	Tak PP and Firestein GS: NF-κB: A key role in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI
16	Dixit V and Mak TW: NF-kappaB signaling: Many roads lead to Madrid. Cell. 111:615–619. 2002. View Article : Google Scholar : PubMed/NCBI
17	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109 (Suppl):S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
18	Naumann M and Scheidereit C: Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J. 13:4597–4607. 1994. View Article : Google Scholar : PubMed/NCBI
19	Sakurai H, Chiba H, Miyoshi H, Sugita T and Toriumi W: IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem. 274:30353–30356. 1999. View Article : Google Scholar : PubMed/NCBI
20	Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V, Shin ML and Rus H: RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. 277:502–508. 2002. View Article : Google Scholar : PubMed/NCBI
21	Schlick SN, Wood CD, Gunnell A, Webb HM, Khasnis S, Schepers A and West MJ: Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells. PLoS One. 6:e286382011. View Article : Google Scholar : PubMed/NCBI
22	Wang JN, Shi N, Xie WB, Guo X and Chen SY: Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration. Arterioscler Thromb Vasc Biol. 31:e19–e26. 2011. View Article : Google Scholar : PubMed/NCBI
23	Guo X, Jose PA and Chen SY: Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells. Am J Physiol Cell Physiol. 300:C1415–C1421. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, Li DM and Zhao Q: Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor β-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res. 31:292012. View Article : Google Scholar : PubMed/NCBI
25	Tang JM, Shi N, Dong K, Brown SA, Coleman AE, Boegehold MA and Chen SY: Response gene to complement 32 maintains blood pressure homeostasis by regulating α-adrenergic receptor expression. Circ Res. 123:1080–1090. 2018. View Article : Google Scholar : PubMed/NCBI
26	Badea TC, Niculescu FI, Soane L, Shin ML and Rus H: Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. 273:26977–26981. 1998. View Article : Google Scholar : PubMed/NCBI
27	Kim DS, Lee JY, Lee SM, Choi JE, Cho S and Park JY: Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. Cancer. 117:590–596. 2011. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI
30	Njikan S, Manning AJ, Ovechkina Y, Awasthi D and Parish T: High content, high-throughput screening for small molecule inducers of NF-κB translocation. PLoS One. 13:e01999662018. View Article : Google Scholar : PubMed/NCBI
31	Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999. View Article : Google Scholar : PubMed/NCBI
32	Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, et al: Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 104:1673–1679. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG and Yang Q: Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci. 103:2092–2101. 2012. View Article : Google Scholar : PubMed/NCBI
34	Kravtsova-Ivantsiv Y, Shomer I, Cohen-Kaplan V, Snijder B, Superti-Furga G, Gonen H, Sommer T, Ziv T, Admon A, Naroditsky I, et al: KPC1-mediated ubiquitination and proteasomal processing of NF-κB1 p105 to p50 restricts tumor growth. Cell. 161:333–347. 2015. View Article : Google Scholar : PubMed/NCBI
35	Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, Shin ML and Rus H: Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. 78:116–122. 2005. View Article : Google Scholar : PubMed/NCBI
36	Lu Y and Hu XB: C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep. 32:2817–2823. 2014. View Article : Google Scholar : PubMed/NCBI
37	Xu R, Shang C, Zhao J, Han Y, Liu J, Chen K and Shi W: Knockdown of response gene to complement 32 (RGC32) induces apoptosis and inhibits cell growth, migration, and invasion in human lung cancer cells. Mol Cell Biochem. 394:109–118. 2014. View Article : Google Scholar : PubMed/NCBI
38	Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW and Liang P: NF-kappaB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 19:841–849. 2000. View Article : Google Scholar : PubMed/NCBI
39	Chen W, Li Z, Bai L and Lin Y: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 16:1172–1185. 2011. View Article : Google Scholar : PubMed/NCBI
40	Tichet M, Prod'Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, et al: Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun. 6:69932015. View Article : Google Scholar : PubMed/NCBI
41	Chen PH, Chang H, Chang JT and Lin P: Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer. Oncogene. 31:2555–2565. 2012. View Article : Google Scholar : PubMed/NCBI
42	Naik NA, Bhat IA, Afroze D, Rasool R, Mir H, Andrabi SI, Shah S, Siddiqi MA and Shah ZA: Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol. 33:833–839. 2012. View Article : Google Scholar : PubMed/NCBI